利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

234 条记录 (耗时 0.034 秒)

    VIRAL VECTOR-DERIVED TARGET PROTEIN FOR ANTICANCER THERAPY AND BINDING MOLECULE OR FRAGMENT THEREOF SPECIFICALLY BINDING THERETO
    1.
    发明公开
    VIRAL VECTOR-DERIVED TARGET PROTEIN FOR ANTICANCER THERAPY AND BINDING MOLECULE OR FRAGMENT THEREOF SPECIFICALLY BINDING THERETO 审中-公开

    公开(公告)号：US20240156865A1

    公开(公告)日：2024-05-16

    申请号：US18281884

    申请日：2021-04-05

    申请人： BIONOXX INC.

    发明人： Tae-Ho HWANG ,  Mongo CHO

    IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/08

    CPC分类号： A61K35/17 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/08 ,  A61K2039/505

    摘要： A target protein for viral vector-based anticancer therapy, and a binding molecule or a fragment thereof which specifically binds thereto are disclosed. A conformational epitope of protein A56, and a binding molecule or a fragment thereof which specifically binds thereto are disclosed. The A56-binding molecule or a fragment thereof, which binds to a conformational epitope of A56 forms a specific structural bond with A56 and shows high affinity thereto. Administering a vaccinia virus-based oncolytic virus, A56 is expressed on the cancer cell surface in various carcinomas. The A56-binding molecule or a fragment thereof effectively targets A56 that is specifically expressed on the cancer cell surface, which enables targeted therapy for cancer cells that have survived even infection with an oncolytic virus, thereby providing effective anticancer therapy.

    Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
    6.
    发明公开
    Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY 审中-公开

    公开(公告)号：US20230174655A1

    公开(公告)日：2023-06-08

    申请号：US17846672

    申请日：2022-06-22

    申请人： Chugai Seiyaku Kabushiki Kaisha

    发明人： Futa Mimoto ,  Taichi Kuramochi ,  Tomoyuki Igawa ,  Hitoshi Katada ,  Shojiro Kadono

    IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K16/08 ,  C07K16/18

    CPC分类号： C07K16/2866 ,  C07K16/303 ,  C07K16/08 ,  C07K16/18 ,  C07K2317/524 ,  C07K2317/72

    摘要： An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of FcγRIIa, types H and R, and having enhanced FcγRIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of FcγRIIa and enhancing the FcγRIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R. It is also found that a polypeptide containing an antibody Fc region that contains an alteration of substituting Pro at position 238 (EU numbering) with Asp and several other alterations, enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R.